4.4 Article

Synthesis and in vitro antileishmanial efficacy of benzyl analogues of nifuroxazide

Journal

DRUG DEVELOPMENT RESEARCH
Volume 82, Issue 2, Pages 287-295

Publisher

WILEY
DOI: 10.1002/ddr.21755

Keywords

cytotoxicity; in vitro; Leishmaniasis; nifuroxazide; nitrofuran; promastigote

Funding

  1. National Research Foundation (NRF) [UID 120191]

Ask authors/readers for more resources

Leishmaniasis is a parasitic disease that lacks an effective vaccine, and the limited treatment options are hindered by drug-resistant strains. Investigation of benzyl analogues of a clinical antibiotic showed promising antileishmanial activity against various Leishmania strains. This research suggests the potential for new antileishmanial agents.
Leishmaniasis is a vector-borne parasitic disease that mostly affects populations in tropical and subtropical countries. There is currently no vaccine to protect against and only a handful of drugs are available to treat this disease. Leishmaniasis is curable, but its eradication and elimination are hindered by the emergence of multidrug resistant strains of the causative pathogens, accentuating the need for new and effective antileishmanial drugs. In search for such agents, nifuroxazide, a clinical antibiotic, was evaluated through investigation of its benzyl analogues for in vitro antileishmanial efficacy against promastigotes of various Leishmania (L.) strains. The monobenzylated analogues 1 and 2 were the most potent of all, possessing nanomolar activities up to 10-fold higher than the parent drug nifuroxazide against all three tested Leishmania strains. Both analogues stand as antipromastigote hits for further lead investigation into their potential to act as new antileishmanial agents.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available